Opto-Oligo is a program supported by INSERM TRANSFERT. It aims at developing novel amphiphilic oligonucleotides in order to increase the cellular internalization of the therapeutic oligonucleotides. As part of the development of the “optoligo hub”, our patented oligonucleotide lipid modification technology has been applied to the modulation of protein expression in various pathologies and several collaborative projects are currently under investigation. The activities consisted of: i) automated synthesis of modified oligonucleotides (50 microM synthesizer, AKTA OP10), ii) analyzes / purifications (HPLC, Dialysis), iii) mass spectrometry characterization MALDI), iv) physicochemical studies (DLS, TEM, Zeta …).